New Drug Application Submitted to U.S. FDA for Ibrutinib in the Treatment of
Two B-Cell Malignancies
If approved, ibrutinib will address a high unmet need in relapsed/refractory
chronic lymphocytic leukemia and relapsed/refractory mantle cell lymphoma
RARITAN, N.J., July 10, 2013
RARITAN, N.J., July 10, 2013 /PRNewswire/ -- Janssen Research & Development,
LLC announced the submission of a New Drug Application for ibrutinib to the
U.S. Food and Drug Administration (FDA) for its use in the treatment of
previously treated patients with chronic lymphocytic leukemia (CLL)/small
lymphocytic lymphoma (SLL), and for its use in the treatment of previously
treated patients with mantle cell lymphoma (MCL). The regulatory submission
for ibrutinib is supported by data from two pivotal Phase 2 studies, one in
relapsed/refractory CLL/SLL (PCYC-1102) and one in relapsed/refractory MCL
(PCYC-1104), both of which were published in The New England Journal of
Medicine online on June 19, 2013. Ibrutinib is a novel Bruton's tyrosine
kinase (BTK) inhibitor being jointly developed by Janssen and Pharmacyclics,
Inc. for the treatment of B-cell malignancies.
If approved, ibrutinib would be the first in a class of oral BTK inhibitors
and is one of the first medicines to file for FDA approval via the new
Breakthrough Therapy Designation pathway. Ibrutinib will be co-commercialized
in the U.S. by Janssen Biotech, Inc. and Pharmacyclics.
"The FDA submission is another important milestone for ibrutinib since we
formed our strategic partnership with Pharmacyclics just 18 months ago," said
Peter F. Lebowitz, M.D., Ph.D., Global Oncology Head, Janssen. "Both companies
recognize that there is great unmet need among these patient populations, and
together in close collaboration with the FDA, as part of its Breakthrough
Therapy Designation pathway, we have been able to accelerate the ibrutinib
development program for the benefit of patients."
Breakthrough Therapy Designation is intended to expedite the development and
review time for a potential new medicine. To date, ibrutinib has been granted
three Breakthrough Therapy Designations by the FDA as a monotherapy for the
treatment of: patients with CLL/SLL with deletion of the short arm of
chromosome 17 (del 17p), patients with relapsed/refractory MCL who have
received prior therapy, and patients with Waldenstrom's macroglobulinemia
CLL/SLL and MCL are hematologic malignancies belonging to a type of cancers
that originate from B-cells (a type of white blood cell, or lymphocyte). (CLL
and SLL are considered to be different manifestations of the same underlying
disease as they share similarities in signs and symptoms, genetic features,
disease progression and treatment.) Data suggest ibrutinib covalently bonds to
BTK in malignant B-cells, shutting down their major growth and survival
About Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia (CLL) is a slow-growing blood cancer that most
commonly originates from B-cells, a type of white blood cell (lymphocyte).
B-cells are part of the immune system and play an important role in fighting
infection in the body. CLL is the most common adult leukemia in the Western
World. Approximately 15,680 patients in the U.S. are diagnosed each year with
CLL. The prevalence of CLL is approximately 113,000 in the U.S. CLL is a
chronic disease of the elderly with a five-year survival rate of approximately
82 percent. Patients commonly receive multiple lines of treatment over the
course of their disease.
In CLL, the genetic mutation del 17p occurs when part of chromosome 17 has
been lost. CLL patients with del 17p have poor treatment outcomes. Del 17p is
reported in seven percent of treatment-naive CLL cases, with approximately 20
to 40 percent of relapsed/refractory patients harboring the mutation. When
cancer cells are located mostly in the lymph nodes, the disease is called SLL.
About Mantle Cell Lymphoma
MCL is a B-cell malignancy, an aggressive type of B-cell non-Hodgkin lymphoma
(NHL) that usually occurs in older adults. The disease typically begins in
the lymph nodes, but can spread to other tissues, such as bone marrow, liver,
and spleen. Patients typically survive an average of five years.
Ibrutinib targets the B-cell receptor pathway via inhibiting BTK, a critical
mediator in malignant B-cell growth and proliferation. In the U.S., there are
approximately 5,000 new cases of MCL each year.
Ibrutinib is an investigational, oral Bruton's tyrosine kinase (BTK)
inhibitor. The effectiveness and safety of ibrutinib alone or in combination
with other treatments is being studied in several B-cell malignancies. Janssen
Biotech, Inc. and Pharmacyclics entered a collaboration and license agreement
in December 2011 to co-develop and co-commercialize ibrutinib. Details about
the complete ibrutinib clinical program are posted on clinicaltrials.gov.
About Janssen Research & Development and Janssen Biotech, Inc.
At Janssen, we are dedicated to addressing and solving some of the most
important unmet medical needs of our time in oncology, immunology,
neuroscience, infectious diseases and vaccines, and cardiovascular and
metabolic diseases. Driven by our commitment to patients, we develop
innovative products, services and healthcare solutions to help people with
serious diseases throughout the world. Beyond its innovative medicines,
Janssen is at the forefront of developing education and public policy
initiatives to ensure patients and their families, caregivers, advocates and
health care professionals have access to the latest treatment information,
support services and quality care.
Janssen Research & Development and Janssen Biotech are two of the Janssen
Pharmaceutical Companies of Johnson & Johnson. Please
visithttp://www.janssenrnd.comor www.janssenbiotech.com for more information
or call 1-800-526-7736 for U.S. medical inquiries. Follow us on Twitter at
(This press release contains "forward-looking statements" as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Janssen Research &
Development, LLC, Janssen Biotech, Inc., any of the other Janssen
Pharmaceutical Companies and/or Johnson & Johnson. Risks and uncertainties
include, but are not limited to, general industry conditions and competition;
economic factors, such as interest rate and currency exchange rate
fluctuations; technological advances, new products and patents attained by
competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; changes in behavior and
spending patterns or financial distress of purchasers of health care products
and services; changes to governmental laws and regulations and domestic and
foreign health care reforms; trends toward health care cost containment; and
increased scrutiny of the health care industry by government agencies. A
further list and description of these risks, uncertainties and other factors
can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K
for the fiscal year ended December 30, 2012. Copies of this Form 10-K, as well
as subsequent filings, are available online at www.sec.gov, www.jnj.com or on
request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies
nor Johnson & Johnson undertake to update any forward-looking statements as a
result of new information or future events or developments.)
 Cancer.net. "Leukemia – Chronic Lymphocytic - CLL".
Accessed June 2013.
 Cancer.net. "Lymphoma – Non-Hodgkin".
 Know Cancer. "Mantle Cell Lymphoma". Available at:
http://www.knowcancer.com/oncology/mantle-cell-lymphoma/. Accessed April 2013.
 Geisler, C. (2010) "Front-line treatment of mantle cell lymphoma."
Haematologica, 95:8:1241-1243. Available at:
SOURCE Janssen Research & Development, LLC
Press spacebar to pause and continue. Press esc to stop.